![]() ![]() “But the treatment landscape in this condition has shifted since the original MIST trial. It affects 100,000 people in the UK, and 2.3 million globally.Ĭhief Investigator Professor John Snowden, Consultant Haematologist at Sheffield Teaching Hospitals NHS Foundation Trust, said: “AHSCT has been shown to be highly effective in stabilising, and even reversing disability, in certain patients with MS. It is the most common chronic inflammatory and neurodegenerative disease of the central nervous system in young adults. The findings could revolutionise care for thousands of people who have MS. They weren't around during the MIST trial, but have since shown great promise in clinical trials. These are Alemtuzumab, ocrelizumab, ofatumumab and cladribine. Each participant will be randomly allocated to receive a stem cell transplant, or one of the four highly effective drugs. The StarMS team aims to recruit up to 200 patients. ![]() In StarMS, experts will test how AHSCT affects patients with highly ‘active’ MS failing drug treatment, or as a first-line treatment for patients with the ‘aggressive’ MS. It also showed AHSCT worked better than MS drugs available at the time in reducing the risk of disability in patients with highly ‘active’ MS. MIST found stem cell transplantation could reverse disability in certain patients with MS. The study builds on results of the landmark MIST trial. It is the first to compare the effectiveness and safety of autologous hematopoietic stem cell transplantation (AHSCT) with four leading highly effective drug treatments.Įxperts at Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield’s Clinical Trials Research Unit are leading the research. The £2.3m StarMS study is funded by an NIHR and Medical Research Council partnership. Their goal is to find drugs that could stimulate the body’s own stem cells to replace the damaged myelin.A world-first trial will test if stem cell transplantation could be used as a first-line treatment for patients with 'highly active' and ‘aggressive’ forms of multiple sclerosis (MS). Other groups have been trying to learn more about how the body’s natural process should be repairing the damage. The idea is that these could be transplanted into a person with multiple sclerosis, and the cells would repair damage caused by the disease. The doctors then transplant in fresh bone marrow cells that repopulate the person’s blood system with immune cells that won’t attack the myelin.Īlthough some people have been successful with this approach, the bone marrow transplant itself is extremely risky.ĬIRM funded researchers have been trying to mature stem cells into a type of cell that might be able to replace the missing myelin. In this approach, powerful chemotherapy agents eliminate a person’s bone marrow cells, which include the blood-forming stem cells that produce the entire blood system including immune cells. Some groups have had success treating MS using bone marrow transplants. About 400,000 people are living with MS in the U.S. Over time the disease progresses and people may end up with more severe symptoms included paralysis. As people lose myelin surrounding their nerves they start feeling weak or having trouble walking. This protective covering is called myelin. Multiple sclerosis occurs when the body’s own immune system attacks the cells that surround and protect neurons. ![]() CIRM funds many projects seeking to better understand multiple sclerosis and to translate those discoveries into new therapies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |